Difference between revisions of "Malignant peritoneal mesothelioma"
Jump to navigation
Jump to search
m |
m |
||
| Line 9: | Line 9: | ||
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div> | <div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div> | ||
|} | |} | ||
| − | |||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
| − | |||
=Guidelines= | =Guidelines= | ||
| − | |||
==EURACAN/PSOGI== | ==EURACAN/PSOGI== | ||
*'''2020:''' Kusamura et al. [https://doi.org/10.1016/j.ejso.2020.02.011 Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up] | *'''2020:''' Kusamura et al. [https://doi.org/10.1016/j.ejso.2020.02.011 Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up] | ||
| − | |||
==[https://www.nccn.org/ NCCN]== | ==[https://www.nccn.org/ NCCN]== | ||
*[https://www.nccn.org/professionals/physician_gls/pdf/mpem.pdf NCCN Guidelines - Malignant Peritoneal Mesothelioma] | *[https://www.nccn.org/professionals/physician_gls/pdf/mpem.pdf NCCN Guidelines - Malignant Peritoneal Mesothelioma] | ||
| − | |||
=Advanced or metastatic disease, subsequent lines of therapy= | =Advanced or metastatic disease, subsequent lines of therapy= | ||
| − | |||
==Atezolizumab & Bevacizumab {{#subobject:8ahgy7|Regimen=1}}== | ==Atezolizumab & Bevacizumab {{#subobject:8ahgy7|Regimen=1}}== | ||
| − | + | <div class="toccolours" style="background-color:#eeeeee"> | |
===Regimen {{#subobject:6d0c87|Variant=1}}=== | ===Regimen {{#subobject:6d0c87|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 60%; text-align:center;" | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
| Line 35: | Line 29: | ||
|- | |- | ||
|} | |} | ||
| + | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Immunotherapy==== | ====Immunotherapy==== | ||
*[[Atezolizumab (Tecentriq)]] 1200 mg IV once on day 1 | *[[Atezolizumab (Tecentriq)]] 1200 mg IV once on day 1 | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1 | *[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1 | ||
| − | |||
'''21-day cycles''' | '''21-day cycles''' | ||
| + | </div></div> | ||
===References=== | ===References=== | ||
#'''MDACC 2016-0861:''' Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM. Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov. 2021 Nov;11(11):2738-2747. Epub 2021 Jul 14. [https://doi.org/10.1158/2159-8290.cd-21-0331 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8563380/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/34261675/ PubMed] NCT03074513 | #'''MDACC 2016-0861:''' Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM. Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov. 2021 Nov;11(11):2738-2747. Epub 2021 Jul 14. [https://doi.org/10.1158/2159-8290.cd-21-0331 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8563380/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/34261675/ PubMed] NCT03074513 | ||
| − | |||
[[Category:Malignant peritoneal mesothelioma regimens]] | [[Category:Malignant peritoneal mesothelioma regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Gastrointestinal cancers]] | [[Category:Gastrointestinal cancers]] | ||
[[Category:Mesotheliomas]] | [[Category:Mesotheliomas]] | ||
Revision as of 17:19, 28 February 2023
1 regimens on this page
1 variants on this page
|
Guidelines
EURACAN/PSOGI
- 2020: Kusamura et al. Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up
NCCN
Advanced or metastatic disease, subsequent lines of therapy
Atezolizumab & Bevacizumab
Regimen
| Study | Years of enrollment | Evidence |
|---|---|---|
| Raghav et al. 2021 (MDACC 2016-0861) | 2017-2019 | Phase 2 |
Immunotherapy
- Atezolizumab (Tecentriq) 1200 mg IV once on day 1
Targeted therapy
- Bevacizumab (Avastin) 15 mg/kg IV once on day 1
21-day cycles
References
- MDACC 2016-0861: Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM. Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov. 2021 Nov;11(11):2738-2747. Epub 2021 Jul 14. link to original article link to PMC article contains dosing details in manuscript PubMed NCT03074513